Study guide

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae

Key Takeaways Explain This Topic AI

Methamphetamine has an elimination half-life of roughly 10 to 12 hours, against about 1 hour for cocaine, which explains its far longer intoxication, binge-crash pattern and prolonged psychosis risk.

Methamphetamine-associated cardiomyopathy is a leading cause of heart failure in adults under 50 who use methamphetamine, and left ventricular function can improve substantially with sustained abstinence.

Methamphetamine-induced psychosis presents with persecutory delusions and tactile hallucinations (formication) in a clear sensorium, which distinguishes it from delirium.

Hyperthermia above 40 degrees Celsius is the strongest predictor of death in acute methamphetamine toxicity, and external cooling plus benzodiazepine sedation precede all other interventions.

Beta-blocker monotherapy is avoided in acute methamphetamine or cocaine toxicity because of the theoretical risk of unopposed alpha stimulation; benzodiazepines are the first-line agent for agitation, tachycardia and hypertension.

Last updated: September 2026

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae

Quick Answer: Methamphetamine reverses the dopamine transporter and VMAT2 , forcing non-vesicular dopamine efflux. Its elimination half-life of about 10 to 12 hours (versus roughly 1 hour for cocaine) produces intoxication lasting 8 to 24 hours , multi-day binges, and psychosis that can outlast drug clearance. Cardinal complications are methamphetamine-associated cardiomyopathy , pulmonary arterial hypertension , intracranial hemorrhage , hyperthermia , rhabdomyolysis , and methamphetamine-induced psychosis with formication . Acute toxicity is treated with benzodiazepines plus aggressive external cooling ; beta-blocker monotherapy is avoided.

Stimulant use disorder is 15% of the CARN-AP blueprint (22–24 items), and the 2025 practice analysis found time spent with stimulant-using patients had risen from 9.69% to 15.74% of APRN practice — the largest shift in the entire survey.

1. Pharmacologic Contrast With Cocaine

  • Feature Cocaine Methamphetamine
  • Primary mechanism Blocks DAT, NET, SERT reuptake Reverses DAT and disrupts VMAT2; also inhibits MAO
  • Elimination half-life About 1 hour (benzoylecgonine metabolite 6+ hours) About 10 to 12 hours
  • Duration of subjective effect 20 to 90 minutes depending on route 8 to 24 hours
  • Local anesthetic/sodium channel effect Yes — contributes to wide-complex dysrhythmia No
  • Typical use pattern Frequent redosing within a session Multi-day binge followed by a crash lasting days
  • Neurotoxicity Primarily vascular Dopaminergic and serotonergic terminal damage; microglial activation

Exam trap: because cocaine blocks fast sodium channels, a wide-complex dysrhythmia in cocaine toxicity is treated with sodium bicarbonate . Methamphetamine has no sodium-channel effect, so a wide QRS in a methamphetamine presentation should prompt a search for a co-ingestant or an alternate cause.

2. Cardiovascular Consequences

Methamphetamine-associated cardiomyopathy (MAC). Catecholamine excess, oxidative stress, mitochondrial injury and repeated ischemia produce a dilated cardiomyopathy that now accounts for a substantial share of heart failure admissions in adults under 50 in high-prevalence regions. Presents as dyspnea, orthopnea, edema and reduced ejection fraction. Left ventricular function can improve markedly with sustained abstinence , which makes this one of the most powerful teaching points available to the APRN: the heart failure is partly reversible, and the medication that treats it best is abstinence combined with guideline-directed heart failure therapy.

Acute coronary syndrome. Coronary vasospasm plus accelerated atherosclerosis and a prothrombotic state. Chest pain in a methamphetamine-using patient is evaluated as ACS, not dismissed as anxiety.

Pulmonary arterial hypertension. Methamphetamine is an established cause; screen with echocardiography when unexplained dyspnea or right heart findings appear.

Aortic dissection and intracranial hemorrhage. Driven by surges of severe hypertension. A methamphetamine-using patient with the worst headache of their life needs imaging, not reassurance.

Dysrhythmia. Sinus tachycardia is typical; QTc prolongation occurs and matters when methadone or antipsychotics are co-prescribed.

3. Neurologic, Dental, Dermatologic and Infectious Complications

System Finding Mechanism and teaching

Neurocognitive Deficits in episodic memory, executive function, processing speed Dopaminergic terminal injury; substantially improves over 12 or more months of abstinence, though not always to baseline

Movement Choreoathetoid movements, bruxism, punding (repetitive purposeless activity) Striatal dopamine excess

Dental "Meth mouth" — rampant caries, especially at the gumline Xerostomia, bruxism, acidic drinks, poor hygiene during binges; not a direct caustic effect of smoked drug

Dermatologic Excoriations on face and forearms Formication (tactile hallucination of insects under the skin) plus punding; secondary staphylococcal infection is common

Infectious HIV, HCV, invasive staphylococcal disease, syphilis Injection practice plus sexualized use ("party and play"); screen at every encounter

  • Obstetric Placental abruption, growth restriction, preterm birth Vasoconstriction
  • 4. Methamphetamine-Induced Psychosis

Presentation: persecutory delusions, auditory hallucinations, and tactile hallucinations (formication) , typically in a clear sensorium with intact orientation.

Distinguishing from delirium: delirium has a fluctuating level of consciousness, disorientation and inattention. A methamphetamine-using patient who is fully oriented, attentive, and describing bugs under the skin has psychosis, not delirium — though hyperthermia and hyponatremia can produce a superimposed delirium.

Distinguishing from primary schizophrenia: methamphetamine-induced psychosis usually resolves within days to weeks of abstinence and is not typically accompanied by prominent negative symptoms or a prodrome. Persistence beyond about a month of verified abstinence should prompt reconsideration of a primary psychotic disorder. Sensitization means psychosis can recur at lower doses and, in some patients, persist for months.

Management: benzodiazepines first for agitation. Antipsychotics are used when psychosis is severe or persists; olanzapine and haloperidol have the best evidence, with attention to QTc and to the risk of impaired heat dissipation in a hyperthermic patient.

5. Acute Toxicity: The Priority Sequence

Temperature first. Hyperthermia above 40 degrees Celsius is the strongest predictor of death. Undress the patient, apply ice packs to the axillae and groin, use evaporative cooling and cooled intravenous fluids. Antipyretics do not work — this is not a hypothalamic set-point fever.

Benzodiazepines. Titrated intravenous lorazepam or diazepam simultaneously treat agitation, tachycardia, hypertension, hyperthermia from muscular hyperactivity, and seizure risk.

Volume and electrolytes. Aggressive intravenous fluids for rhabdomyolysis; check creatine kinase, potassium, creatinine, and sodium (hyponatremia from water intoxication is common at dance events).

Hypertension refractory to benzodiazepines. Use phentolamine (alpha blockade), nicardipine , or nitroglycerin/nitroprusside . Avoid beta-blocker monotherapy because of the theoretical risk of unopposed alpha-mediated vasoconstriction.

Do not use physical restraint alone. Restraint without adequate sedation drives continued isometric muscular activity, worsening hyperthermia, rhabdomyolysis and metabolic acidosis, and has been implicated in sudden deaths.